Member Info for Rookie72

The post you shared appears to be mixing together information from two completely different companies:

genedrive plc

CelLBxHealth plc

The quoted text about the “largest private US healthcare provider”, “Parsortix® platform”, and “top ten global pharmaceutical company” is related to CelLBxHealth / Parsortix — not Genedrive. �

Investegate +2

So the claim that “CLBX and GDR going to run hard” is partly speculation from traders combining biotech momentum stocks together.

If a farm-out deal fails, Petro Matad's best strategy is to pivot from a "risky explorer" to a "disciplined producer." They must stop looking for new oil and focus entirely on squeezing cash out of what they have already found.Here is the best path forward to protect the share price and ensure survival:1. Maximize "Low-Hanging Fruit" (Heron-1 & Gazelle-1)Without a partner to fund new exploration, the company must focus every penny on its two existing discoveries.The Goal: Optimize production to reach a combined 500–700 barrels per day.The Outcome: At current oil prices, this would generate roughly $8M–$10M in annual revenue after government royalties. This is enough to cover all overheads and leave a surplus for small-scale projects.2. Focus on "Appraisal" over "Exploration"Exploration is a gamble; appraisal is a calculation.The Shift: Instead of drilling high-risk wildcat wells in Block XX, they should drill Heron-3 or Heron-4.Why: These are locations very close to known oil. The chance of success is much higher (80%+ vs. 20%). Proving the size of the Heron field increases the company's "book value," making them a more attractive takeover target later.3. Aggressive Cost CuttingThe company’s overhead (corporate offices, staff, listing fees) is built for a company planning to grow fast.The Move: Without a partner, they must shrink. This means reducing non-essential staff and possibly delaying the 200MW renewable project, which, while exciting, is a distraction for a cash-strapped oil firm.4. Direct Exporting to ChinaCurrently, they are often reliant on local intermediaries or specific PetroChina terms.The Move: Investing in their own trucking fleet or small-scale local storage would allow them to sell oil more consistently. This prevents "shut-ins" (stopping production because there is nowhere to put the oil), which has historically hurt their cash flow.📉 The "Worst Case" to AvoidIf they cannot find a partner and try to "go it alone" by raising more money from the stock market (a placing):Dilution: Issuing new shares at a discount would likely crash the price toward 0.80p – 1.00p.Investor Fatigue: Existing shareholders are tired of funding exploration that hasn't yielded a massive payout yet.

Everything is still speculative, until they are proven. You can it is worth this! But until the oil is taken out of the ground, it is worth jack.

It does not sit right, there is no clear plans for drilling....

David,

You are a breath of fresh air, I'm in very deep water, probably the same fir many people on here. But I hope what you have managed to do...has turned the tides. I for one are looking forward to the FDA submission and approval fingers crossed! What do you think of our chances of getting back to the price at it's highest during the beginning of COVID?

After March general meeting, if approved

Unfortunately everything StockMaiden said is true!!

It just feel too little, too late, all the time with this company...always something new pops up! Licence, land access, producers, tax.... I'm exhausted how long it too for us to get to this point and it is not 100% ironed out, what new spanner in the works going to turn up? It has been 4/5 yrs since we found oil! Talking about moving at snail pace, beggers believe.

Does anyone know anything? Everything gone very quiet!!

Does anyone have the link to the recent presentation please?

I can't seem to find the recent presentation, can anyone share me the link please?

1 “At current production and oil prices, can MATD fund all operations for the next 12 months without raising equity?”

2 “What production level must be maintained for MATD to remain cash-flow positive, and how confident are you that this can be sustained without further drilling?”

3 “Will management commit to not drilling or expanding unless projects are fully funded from cash flow or non-dilutive finance?”

MB mentioned of dividend payments to shareholders in his last presentation....the question for him this time is, when is likely to deliver this dividend to it's shareholders??

Smartass more like, you sound like wos!

They haven't even submitted to FDA, grrr

What's everyone's opinion when we're likely to get concrete news regarding FDA approval? Whether it is good or bad or indifference.?

Key weekly figures (GBP, rounded)

All calculations use the 1H-2025 consolidated statement of comprehensive income.

Revenue (operating income): USD 1,403,000 → £1,080,000 total for 6 months.

→ Per week: £41,550.

Cost of goods sold: USD 384,000 → £296,000 total.

→ Per week: £11,360.

Employee benefits (salaries/payroll): USD 726,000 → £559,000 total.

→ Per week (salaries): £21,506.

Other cash operating costs (consultancy + exploration + other expenses):

Consultancy USD 69k, Exploration USD 84k, Other expenses USD 1,178k → combined USD 1,331,000 → £1,024,000 total.

→ Per week: £39,385.

Depreciation & amortisation (non-cash): USD 649,000 → £500,000 total.

→ Per week: £19,223.

---

Net result per week (two views)

1. Accounting net (including depreciation) — this is the reported P&L outcome:

Profit/(Loss) for 1H2025 = USD -1,670,000 → £ -1,287,000 total.

Net per week: £ -49,500 loss per week.

2. Cash-style operating net (exclude non-cash depreciation) — approximate cash effect:

Revenue minus COGS minus salaries minus other cash operating costs = USD 1,403k − (384k + 726k + 1,331k) = USD -1,038k → £ -799,000 total.

Cash net per week: £ -30,700 loss per week (approx).

Key weekly figures (GBP, rounded)

All calculations use the 1H-2025 consolidated statement of comprehensive income.

Revenue (operating income): USD 1,403,000 → £1,080,000 total for 6 months.

→ Per week: £41,550.

Cost of goods sold: USD 384,000 → £296,000 total.

→ Per week: £11,360.

Employee benefits (salaries/payroll): USD 726,000 → £559,000 total.

→ Per week (salaries): £21,506.

Other cash operating costs (consultancy + exploration + other expenses):

Consultancy USD 69k, Exploration USD 84k, Other expenses USD 1,178k → combined USD 1,331,000 → £1,024,000 total.

→ Per week: £39,385.

Depreciation & amortisation (non-cash): USD 649,000 → £500,000 total.

→ Per week: £19,223.

---

Net result per week (two views)

1. Accounting net (including depreciation) — this is the reported P&L outcome:

Profit/(Loss) for 1H2025 = USD -1,670,000 → £ -1,287,000 total.

Net per week: £ -49,500 loss per week.

2. Cash-style operating net (exclude non-cash depreciation) — approximate cash effect:

Revenue minus COGS minus salaries minus other cash operating costs = USD 1,403k − (384k + 726k + 1,331k) = USD -1,038k → £ -799,000 total.

Cash net per week: £ -30,700 loss per week (approx).

You sound just like WOS!!

Shouldn't do, but strangely it went up today, even when the sell are higher than buy.